Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR448501 in Systemic Lupus Erythematosus and Rheumatoid Arthritis
NCT06647069Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 5
01
Overview
Phase 1, open-label trial of dr-0201 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoints: Incidence of treatment-emergent adverse events at 52 weeks and Incidence of potentially clinically significant abnormalities at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
dr-0201
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06647069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647069.